Advancements and Prospect in Microbial Pharmaceuticals
DOI:
https://doi.org/10.54097/66d8qr62Keywords:
Microbial Pharmaceuticals, Antibiotic Resistance, Drug Development, Artificial Intelligence, AntibioticsAbstract
Microbial pharmaceuticals are a vital pillar of modern medicine, playing a critical role in the treatment of infectious diseases, cancer, and immune-related disorders. This paper systematically reviews advancements in microbial pharmaceuticals over the past decade, categorizing them into three main types based on their sources, with a focus on representative drugs such as antibiotics, amino acids, and nucleotides. While significant clinical successes have been achieved, challenges persist, including bacterial resistance, inefficiencies in drug screening, limited diversity, and concerns regarding side effects and toxicity. To address these issues, this paper outlines future development prospects, summarized into four key directions. By integrating multidisciplinary technological approaches and innovative strategies, microbial pharmaceutical research is poised to make transformative advances in addressing global health challenges.
Downloads
References
[1] Singh, B. K., & Macdonald, C. A. (2010). Drug discovery from uncultivable microorganisms. Drug Discovery Today, 15(17-18), 792-799.
[2] Ju, J. H., Yang, Z. Y., Li, Q. L., et al. (2021). Current status and reflections on the research and development of microbial drugs. Journal of Shandong University (Medical Edition), 59(09), 43-50, 63.
[3] Wu, X. T., Zhang, R. F., Yan, X. Y., et al. (2023). Nanozyme: a new approach for antimicrobial infections. Journal of Inorganic Materials, 38(1), 43-54.
[4] Jeon, G., & Ahn, J. (2020). Assessment of phage-mediated inhibition of Salmonella Typhimurium treated with sublethal concentrations of ceftriaxone and ciprofloxacin. FEMS Microbiology Letters, 367(19).
[5] Tian, E. K., Wang, Y., Wu, Z. X., et al. (2021). Bacteriophage therapy: Retrospective review and future prospects. Journal of Sichuan University (Medical Science Edition), 52(2), 170-175.
[6] Aorigele. (2024). The role of scorpion venom antimicrobial peptides in pathogenic microorganism infections. Journal of Pathogen Biology, 19(12), 1521-1524.
[7] Ma, L. (2022). Process optimization and impurity control of arginine glutamate injection [D].
[8] Zhang, Z. L. (2022). Structural analysis and transport mechanism study of glutamate transporter hEAAT2 as a target for microbial drug screening [D].
[9] Shen, X., Han, G. J., Zhao, J. H., et al. (2021). Research progress on nucleoside (acid) antiviral drugs. Journal of Changchun Normal University, 40(10), 86-90.
[10] You, H., Wang, F. S., Li, T. S., et al. (2023). Guidelines for the prevention and treatment of chronic hepatitis B (2022 edition). Journal of Practical Hepatology, 26(03), 457-478.
[11] Yang, L., Xie, F., & Hu, C. (2023). A novel antisense oligonucleotide drug for treating chronic hepatitis B—bepirovirsen. Journal of Clinical Pharmacotherapy, 21(03), 12-17.
[12] Lu, D. J., Qu, C. X., Li, D. Y., et al. (2023). Prospects for the application of antisense oligonucleotide drugs in the treatment of chronic hepatitis B. Chinese Journal of Viral Diseases, 13(06), 447-453.
[13] Huang, S. (2023). Study on a brain-targeting biomimetic nanodelivery system for antisense oligonucleotides in Parkinson’s disease [D].
[14] Shi, Q. H., Qin, B., & You, S. (2020). Research progress on enzymes as therapeutic drugs. Microbiology Bulletin, 47(07), 2193-2206.
[15] Triplett, T. A., Garrison, K. C., Marshall, N., et al. (2018). Reversal of indoleamine 2,3-dioxygenase-mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme. Nature Biotechnology, 36(8), 758-764.
[16] Wan, S. L., Yang, G., & Ye, Y. (2020). Applications of novel carriers and technologies in therapeutic enzyme research. Chinese Journal of Biomedical Engineering, 39(01), 114-118.
[17] Zhang, J., & Xu, H. H. (2023). Current status and mechanism analysis of clinical applications of antibiotic drugs. Chinese Journal of Drug Abuse Prevention and Treatment, 29(06), 999-1001, 11.
[18] Li, X. N., Chai, Y., & Liu, M. L. (2015). Research progress on the mechanisms and resistance of quinolone antibiotics. Foreign Medicine (Antibiotic Volume), 36(03), 97-102.
[19] Wang, W. Z. (2020). A brief discussion on the clinical application of quinolone antibiotics. Electronic Journal of General Dentistry, 7(03), 14.
[20] Liu, M. Y., Wang, L. L., Dong, T. Q., et al. (2021). Mechanisms of action of antimicrobial drugs and their research progress. Guangdong Chemical Industry, 48(15), 125-126.
[21] Hou, J., Xia, Y. Z., & Li, J. (2024). Research progress on novel β-lactam/β-lactamase inhibitor combination formulations: cefepime-tazobactam. Infectious Disease Pharmacology, 21(10), 983-987.
[22] Zhang, L. J., An, S. H., Wang, Y. Y., et al. (2021). Clinical features of macrolide-resistant Mycoplasma pneumoniae pneumonia with pulmonary consolidation. Clinical Misdiagnosis and Mismanagement, 34(04), 54-58.
[23] Wang, Y. L., Xie, X. Q., Zhao, Z. Y., et al. (2020). Clinical application research progress of the novel aminoglycoside drug plazomicin. Chinese Journal of Clinical New Medicine, 13(12), 1273-1277.
[24] Yuan, G. Y., Wang, M. L., Yu, X. L., et al. (2020). Mechanisms of bacterial resistance and countermeasures. Foreign Medicine (Antibiotic Volume), 1-9.
[25] Christaki, E., Marcou, M., & Tofarides, A. (2020). Antimicrobial resistance in bacteria: mechanisms, evolution, and persistence. Journal of Molecular Evolution, 88(1), 26-40.
[26] Li, J. W., & Vederas, J. C. (2009). Drug discovery and natural products: end of an era or an endless frontier? Science, 325(5937), 161-165.
[27] Leavell, M. D., Singh, A. H., & Kaufmann-Malaga, B. B. (2020). High-throughput screening for improved microbial cell factories: Perspective and promise. Current Opinion in Biotechnology, 62, 22-28.
[28] Newman, D. J., & Cragg, G. M. (2020). Natural products as sources of new drugs over nearly four decades (01/1981 to 09/2019). Journal of Natural Products, 83(3), 770-803.
[29] Krause, K. M., Serio, A. W., Kane, T. R., et al. (2016). Aminoglycosides: An overview. Cold Spring Harbor Perspectives in Medicine, 6(6).
[30] Alshannaq, A., & Yu, J. H. (2017). Occurrence, toxicity, and analysis of major mycotoxins in food. International Journal of Environmental Research and Public Health, 14(6).
[31] Li, Y., Li, X., Wang, G., et al. (2025). Meta-analysis of the impact of genetic polymorphisms on voriconazole blood concentrations in patients with invasive fungal infections. Chinese Pharmacy, 36(02), 225-231.
[32] Zhao, Q., Chen, Y., Huang, W., et al. (2023). Drug-microbiota interactions: An emerging priority for precision medicine. Signal Transduction and Targeted Therapy, 8(1), 386.
[33] Mu, R. M. (2023). Research on funding constraints and solutions in innovative drug development [Master’s thesis].
[34] Ma, X. H. (2025). Research on the novel broad-spectrum tetracycline antibiotic eravacycline. Foreign Medicine (Antibiotics Volume), 46(01), 39-44.
[35] Liu, M. K., Chen, J. J., Dharmasiddhi, I. P. W., et al. (2024). Review of the potential of probiotics in disease treatment: Mechanisms, engineering, and applications. Processes, 12(2), 14.
[36] Ju, Y., Wang, X., Wang, Y., et al. (2022). Application of metagenomic and culturomic technologies in fecal microbiota transplantation: A review. Chinese Journal of Biotechnology, 38(10), 3594-3605.
[37] Feng, Y., Ma, X. J., Wu, Y. L., et al. Application of artificial intelligence large language models in drug target discovery. Life Sciences, 1-19.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
